Average Age, y HT Regimen Vascular Disease Follow-up Any Stroke, HR mg of MPA (n=1380) vs vs placebo Yes (CVD); nondisabling ischemic stroke or TIA within preceding 90 d (CVD) mg of MPA (n=1380) vs Yes (CAD) 6.8 y (2.7-y unblinded follow- up to HERS) Open HT, 494; open control, 494; blind HT, 404; blind Open HT, 58.6; open control, 58.9; blind HT, 58.5; blind placebo, 59 CEE 0.625 mg/d plus 2.5 mg/d MPA or CEE 0.625 mg/d plus 5 mg/d MPA, if <3 y had passed since menopause at recruitment Randomly allocated (open label, n=1006) to HT (n=502) or no 49.7 Intact uterus: 2 mg of synthetic 17 -estradiol for plus 1 mg of norethisterone acetate for 10 d, and 1 mg of 17 -estradiol for 6 d. Prior hysterectomy: 17 - estradiol 2 mg/d. Enrolled within 24 mo of last menses. No* 11 y (randomized treatment phase) and continued observational follow-up (16 y) CAD indicates coronary artery disease; CEE, conjugated equine estrogen; CI, confidence interval; CVD, cardiovascular disease; DOPS, Danish Osteoporosis Prevention Study; HERS, Heart and Estrogen/Progestin Replacement Study; HR, hazard ratio; HT, hormone therapy; MPA, medroxyprogesterone acetate; WEST, Women s Estrogen for Stroke Trial; and WHI, Women s Health Initiative trial for women with a uterus (CEE+MPA) or without a uterus (CEE). *Self-reported as no history of acute myocardial infarction, stroke, or transient ischemic attack in the previous 6 months.259 Bushnell et al Guidelines for Prevention of Stroke in Women 1563 CI, 1.03 1.58; P for trend=0.02). There was, however, no trend for increased stroke based on years since menopause.267 The Estonian trial of HT, a study of women 50 to 64 years of age, also confirmed the findings of the WHI, with a trend toward an increase in cerebrovascular events in women taking (Table 9). 